BioSpace News Archive

Leading orthopedic surgeon to provide medical insight and guidance as company develops the Tbit™ System for objective diagnosis of concussions and other traumatic brain injuries.

The study is the first to investigate a peripherally-acting mu-opioid receptor antagonist (PAMORA) over the course of 52 weeks in a randomized, placebo-controlled and double-blind manner.

Top-line data expected by the end of 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018, at 8:40 a.m. Eastern Time in Boston.

Test only reports 3 out of more than 1,000 known BRCA mutations and negative result doesn’t rule out increased cancer risk

Authorization allows 23andMe to report on BRCA1- and BRCA2-related genetic risk for breast, ovarian and prostate cancer

The U.S. Food and Drug Administration today expanded the approval of a heart valve to include a size small enough to be used in newborn pediatric patients to treat heart defects.

Rocket enters 2018 as a public company with solid financial position following successful completion of merging with Inotek Pharmaceuticals.

Company dedicated to meeting the need for critical, hard-to-find medications with ease of access

EHR-agnostic care plans include specialized protocols for treatment of individuals with opioid addiction.